Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like ProQR Therapeutics Spins Out CNS-Focused Biotech, September 11, 2017 Anpac Bio-Medical Science CEO Keynote Speaker At * Monday, July 11, 2016 July 8, 2016 Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression November 8, 2017
Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression November 8, 2017